Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our USA, Spain, Australia, France, Italy, Brazil, UK, Belgium, Japan, Austria, Taiwan, China, Denmark, Canada, Germany, South Korea, Netherlands and Czechia registers with Servier Bio-Innovation as lead sponsor.Synced 27 Sep 2026
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance
Servier Bio-Innovation is the lead sponsor of 5 current clinical trials
in our USA, Spain, Australia, France, Italy, Brazil, UK, Belgium, Japan, Austria, Taiwan, China, Denmark, Canada, Germany, South Korea, Netherlands and Czechia registers.
2 are recruiting patients now. The most common phase is Phase 1/2. The drugs named most often in its trials are Ivosidenib, S095029 and Cemiplimab. The most-studied condition is Non-small Cell Lung Cancer (NSCLC).
ClinicalTrials.gov trials by status
Recruiting240%
Active, closed360%
Trials by phase
Phase 1/2360%
Phase 3120%
Phase 1120%
01
Clinical trials sponsored by Servier Bio-Innovation
NCT06127407 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
02
Drugs in Servier Bio-Innovation trials
6 compounds
Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
Non-small Cell Lung Cancer (NSCLC)1MSI-H/dMMR Gastroesophageal-junction Cancer1MSI-H/dMMR Gastric Cancer1Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen1MTAP-deleted Solid Tumors1IDH1-Mutated Malignancies1
Sponsors with the most current trials registered for this condition.
06
Questions about Servier Bio-Innovation trials
How many clinical trials does Servier Bio-Innovation sponsor?
Servier Bio-Innovation is the lead sponsor of 5 current trials on ClinicalTrials.gov in our USA, Spain, Australia, France, Italy, Brazil, UK, Belgium, Japan, Austria, Taiwan, China, Denmark, Canada, Germany, South Korea, Netherlands and Czechia registers, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.
Are Servier Bio-Innovation trials recruiting?
Yes. 2 of its 5 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Which drugs is Servier Bio-Innovation testing?
Its current trials name 6 drugs and biologicals as interventions. The most frequent are Ivosidenib (2), S095029 (2), Cemiplimab (1), Keytruda (1) and Pembrolizumab (1). The number in brackets is how many of its trials name each drug.
Where does this information come from?
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
How this page is built
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 27 Sep 2026.
Please verify before you rely on this.
This page is general information for life-science and pharmaceutical professionals. It is
not medical advice, and it has not been reviewed by a clinician — our editorial
team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most
recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC)
and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not
automatically interchangeable, and approvals, brand names and indications differ between the US, the
EU/Ireland (EMA/HPRA) and other regions.
Spotted an error? Tell us — we correct promptly and log it.
We value your privacy
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.